BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary light-chain (AL) amyloidosis.
- You are 18 years or older.
- You have measurable disease, meaning certain protein levels in your blood are high enough.
- You are in reasonably good health (ECOG performance status 0-2).
- Your organs (kidneys, liver, bone marrow) function well enough per lab tests.
- You agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new cell therapy using your own immune cells (genetically modified to target amyloid-producing cells) to treat light chain amyloidosis that hasn't responded to standard treatments. The goal is to help patients whose disease has come back or stopped responding to previous therapies.
This trial tests a combination of two targeted drugs for people newly diagnosed with AL amyloidosis. You may qualify if you have a specific genetic marker (t(11;14)) and your organs are working well enough.
This study tests a new drug that targets two proteins on the cells causing amyloidosis, aiming to reduce the harmful protein buildup in the body. It is for people who have just been diagnosed with this condition and have not yet had other treatments for it.
This trial tests a type of immunotherapy called CAR T cells that target a protein called BCMA on abnormal cells. It is for people whose light chain amyloidosis has come back or not responded to previous treatments.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
Hear when a new Systemic Light Chain Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.